Ocular Therapeutix Total Non-Operating Income/Expense 2013-2024 | OCUL

Ocular Therapeutix total non-operating income/expense from 2013 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.

Ocular Therapeutix Total Non-Operating Income/Expense 2013-2024 | OCUL

Ocular Therapeutix total non-operating income/expense from 2013 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$86.1B
Takeda Pharmaceutical (TAK)$45.9B
Merck (MKGAF)$21.6B
Astellas Pharma (ALPMY)$21.1B
Sandoz Group AG (SDZNY)$17.8B
United Therapeutics (UTHR)$15.8B
Summit Therapeutics (SMMT)$13.8B
Shionogi (SGIOY)$12.6B
Neurocrine Biosciences (NBIX)$11.5B
Catalent (CTLT)$11B
Orion OYJ (ORINY)$8B
Jazz Pharmaceuticals (JAZZ)$6.8B
Ionis Pharmaceuticals (IONS)$5.5B
Hikma Pharmaceuticals Plc (HKMPF)$5.5B
Corcept Therapeutics (CORT)$4.7B
Madrigal Pharmaceuticals (MDGL)$4.5B
Crinetics Pharmaceuticals (CRNX)$4.3B
Dyne Therapeutics (DYN)$3.3B
PTC Therapeutics (PTCT)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.4B
Arrowhead Pharmaceuticals (ARWR)$2.3B
Soleno Therapeutics (SLNO)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
Harrow (HROW)$1.8B
Recursion Pharmaceuticals (RXRX)$1.7B
NewAmsterdam Pharma (NAMS)$1.6B
Ardelyx (ARDX)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
Indivior (INDV)$1.4B